|
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Clinical research trials and Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE). Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) clinical trial. Participants frequently get the best healthcare available for their Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)  Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
For Condition: Arrhythmia,Cardiovascular Diseases,Heart Arrest,Heart Diseases,Myocardial Infarction,Ventricular Fibrillation
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
Details: BACKGROUND: Sudden cardiac death can usually be attributed to the occurrence of the cardiac arrhythmia, ventricular fibrillation. Although a significant proportion of patients experiencing sudden cardiac death may be successfully resuscitated without disabling sequelae, this event tends to recur. Recurrent sudden cardiac death is more common among patients demonstrating certain clinical characteristics such as: ventricular fibrillation occurring in a setting of a remote prior transmural infarction; the presence of abnormal left ventricular function; male gender; concurrent complex ventricular arrhythmias identified by electrocardiographic monitoring; extensive coronary artery disease; and the ability to induce ventricular arrhythmias following electrical stimulation. Multiple therapeutic approaches are offered to patients surviving primary ventricular fibrillation. In those with evidence of myocardial ischemia, coronary revascularization procedures may be employed. Pharmacological therapy with anti-arrhythmic agents either alone or in combination with selection guided by the results of continuous electrocardiographic monitoring or electrophysiologic studies is often the initial step. For those patients refractory to medical therapy, ventricular resection or implantation of pacemakers has been employed. Amiodarone, a unique antiarrhythmic agent with complex pharmacokinetics and substantial potential toxicity, has been utilized when other antiarrhythmic agents failed. The agent was released as an oral agent for the treatment of ventricular fibrillation in the United States by the FDA. Several investigations suggested that amiodarone was efficacious in the treatment of ventricular fibrillation when other available agents had failed. DESIGN NARRATIVE: Patients were stratified by presence or absence of coronary artery disease, left ventricular function, and presence or absence of drug failure prior to randomization. All patients underwent an evaluation of left ventricular ejection fraction, usually by radionuclide ventriculography, and baseline drug-free Holter recording or electrophysiologic study, or both. A total of 113 patients were randomized to amiodarone and 115 patients to conventional therapy with other antiarrhythmic agents which included procainamide, quinidine, disopyramide, tocainide, mexiletine, encainide, flecainide, propafenone, moricizine, or combination therapy in that order. Holter exams were given at one, three, six, twelve, twenty-four, and thirty-six months. Patients were followed for one to five years, with an average of three years overall. Primary endpoints for the study included in the term 'cardiac survival' were cardiac mortality, resuscitated cardiac arrest due to documented ventricular fibrillation, and complete syncope followed by a shock from an automated implanted defibrillator. These endpoints included sudden arrhythmic cardiac death, resuscitated out-of-hospital ventricular fibrillation, and nonarrhythmic cardiac death. A patient death due to amiodarone pulmonary toxicity was also considered a primary endpoint.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: Men and women with ventricular fibrillation who had survived an out-of-hospital cardiac arrest not associated with a Q-wave acute myocardial infarction.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
H.Greene, , University of Washington
Additional Information:
Study ID Numbers: 53;
Study Start Date: April 1987
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000464
Other Heart Diseases Studies:
1. Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients with Implantable Cardioverter Defibrillators
2. Public Access Defibrillation (PAD) Community Trial
3. Technology Dependency and Health-Related Quality of Life
4. Beta-Blocker Heart Attack Trial (BHAT)
5. Digitalis Investigation Group (DIG)
Related Studies:
Other Heart Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
|
|
|
|
|
|
|
|
